2019
Feasibility Studies of an Insulin-Only Bionic Pancreas in a Home-Use Setting
Ekhlaspour L, Nally LM, El-Khatib FH, Ly TT, Clinton P, Frank E, Tanenbaum ML, Hanes SJ, Selagamsetty RR, Hood K, Damiano ER, Buckingham BA. Feasibility Studies of an Insulin-Only Bionic Pancreas in a Home-Use Setting. Journal Of Diabetes Science And Technology 2019, 13: 1001-1007. PMID: 31470740, PMCID: PMC6835195, DOI: 10.1177/1932296819872225.Peer-Reviewed Original ResearchConceptsUsual care armStudy armsOpen-label non-randomized studyHome-use settingDaily insulin doseNon-randomized studiesCare armUsual careInsulin doseIncreased riskMean ageDiabetes burdenGlycemic outcomesHypoglycemic riskIntervention periodAverage glucoseBody weightConsecutive weeksBionic pancreasDynamic glucoseSignificant differencesDlInsulinFactor testingRiskA Feasibility Study to Detect Neonatal Hypoglycemia in Infants of Diabetic Mothers Using Real-Time Continuous Glucose Monitoring
Nally LM, Bondy N, Doiev J, Buckingham BA, Wilson DM. A Feasibility Study to Detect Neonatal Hypoglycemia in Infants of Diabetic Mothers Using Real-Time Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2019, 21: 170-176. PMID: 30839229, DOI: 10.1089/dia.2018.0337.Peer-Reviewed Original ResearchConceptsHours of lifeBlinded continuous glucose monitorContinuous glucose monitorGlucose checksAsymptomatic hypoglycemiaBlood glucoseRM groupPredictive valueTime Continuous Glucose MonitoringWeeks of gestationGroups of infantsFear of painNegative predictive valuePositive predictive valueContinuous glucose monitoringResearch staffDiabetic mothersHypoglycemic episodesNeonatal hypoglycemiaCGM useHypoglycemiaFull cohortClinical staffInfantsHospital standards
2015
Gene therapy with neurogenin3, betacellulin and SOCS1 reverses diabetes in NOD mice
Li R, Buras E, Lee J, Liu R, Liu V, Espiritu C, Ozer K, Thompson B, Nally L, Yuan G, Oka K, Chang B, Samson S, Yechoor V, Chan L. Gene therapy with neurogenin3, betacellulin and SOCS1 reverses diabetes in NOD mice. Gene Therapy 2015, 22: 876-882. PMID: 26172077, PMCID: PMC4636470, DOI: 10.1038/gt.2015.62.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsBasic Helix-Loop-Helix Transcription FactorsBetacellulinDiabetes Mellitus, ExperimentalFemaleGenetic TherapyImmunosuppression TherapyInsulinIslets of LangerhansIslets of Langerhans TransplantationLiverMiceMice, Inbred NODNerve Tissue ProteinsSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling ProteinsConceptsSuppressor of cytokine signaling 1NOD miceGene therapyModel of autoimmune diabetesDiabetic miceLineage-defining transcription factorsGlucose-stimulated insulin secretionHelper-dependent adenovirusActivated T cellsLong-term reversal of diabetesRat insulin promoterReversal of diabetesShortage of donor isletsIslet neogenesisOverexpression suppressorIslet growth factorsNeo-isletsType 1 diabetesCytokine signaling 1Transcription factorsTransfer diabetesNon-obeseTreated mice liverAutoimmune diabetesT cells